The evolving role of drug metabolism in drug discovery and development

Pharmaceutical Research

Volumn 24, Issue 5, 2007, Pages 842-858

  Yengi, Lilian G ^a   Leung, Louis ^a   Kao, John ^a  

^a PFIZER INC   (United States)

Author keywords

Drug discovery and development; Drug interactions clearance; Drug metabolism; Exposure; Idiosyncratic drug toxicity; Inhibition; Integration of emerging sciences; Pharmacogenetics; Pharmacogenomics; Transporters

Indexed keywords

ATORVASTATIN; CARBAMAZEPINE; CELL NUCLEUS RECEPTOR; CLARITHROMYCIN; CLOZAPINE; CYTOCHROME P450; DAPSONE; DICLOFENAC; DIGOXIN; DRUG METABOLIZING ENZYME; FEXOFENADINE; GENE PRODUCT; HALOTHANE; INDOMETACIN; ISONIAZID; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PARACETAMOL; PHENACETIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; TACRINE; TALINOLOL; TAMOXIFEN; TICLOPIDINE; TIENILIC ACID; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

DRUG CLEARANCE; DRUG DISCOVERY; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSPORT; ENZYME INDUCTION; ENZYME REGULATION; FOOD DRUG INTERACTION; FRUIT JUICE; GENOTYPE; HUMAN; METABOLIC ACTIVATION; MULTIGENE FAMILY; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TOXICOGENETICS; TRANSCRIPTION REGULATION;

ANIMALS; DRUG DESIGN; HUMANS; METABOLIC DETOXICATION, DRUG; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 34247631742     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9217-9     Document Type: Review

References (197)

1. J. Axelrod. The enzymatic deamination of amphetamine (benzedrine) J. Biol. Chem. 214:753-763 (1955).
2. R. I. Dorfman, J. W. Cook, and J. B. Hamilton. Conversion by the human of the testis hormone, testosterone, into the urinary androgen, androsterone J. Biol. Chem. 130:285-295 (1939).
3. E. C. Miller, J. A. Miller, R. R. Brown, and J. C. Macdonald. On the protective action of certain polycyclic aromatic hydrocarbons against carcinogenesis by aminoazo dyes and 2-acetylaminofluorene Cancer Res. 18:469-477 (1958).
4. G. C. Mueller and J. A. Miller. The metabolism of 4- dimethylaminoazobenzene by rat liver homogenates J. Biol. Chem. 176:535-544 (1948).
5. G. C. Mueller and J. A. Miller. The metabolism of methylated aminoazo dyes. II. Oxidative demethylation by rat liver homogenates J. Biol. Chem. 202:579-587 (1953).
6. K. J. Ryan. Conversion of androstenedione to estrone by placental microsomes Biochim. Biophys. Acta 27:658-659 (1958).
7. R. T. Williams. Detoxication Mechanisms: The Metabolism of Drugs and Allied Organic Compounds, Chapman and Hall, London, 1949.
8. R. T. Williams. Detoxication Mechanisms: The Metabolism and Detoxication of Drugs, Toxic Substances, and Other Organic Compounds, Chapman and Hall, London, 1959.
9. P. D. Josephy, F. P. Guengerich, and J. O. Miners. Phase I and II drug metabolism: terminology that we should phase out? Drug Metab. Rev.37:575-580 (2005).
10. H. S. Mason. Mechanisms of oxygen metabolism Science 125:1185-1188 (1957).
11. D. Y. Cooper, S. Levin, S. Narasimhulu, and O. Rosenthal. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems Science 147:400-402 (1965).
12. T. Omura and R. Sato. A new cytochrome in liver microsomes J. Biol. Chem. 237:1375-1376 (1962).
13. R. W. Estabrook, D. Y. Cooper, and O. Rosenthal. The light reversible carbon monoxide inhibition of the steroid C21-hydroxylase system of the adrenal cortex Biochem. Z. 338:741-755 (1963).
14. A. Y. Lu and M. J. Coon. Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes J. Biol. Chem. 243:1331-1332 (1968).
15. R. W. Estabrook. A passion for P450s (rememberances of the early history of research on cytochrome P450) Drug Metab. Dispos. 31:1461-1473 (2003).
16. F. P. Guengerich. Cytochrome P450: what have we learned and what are the future issues? Drug Metab. Rev. 36:159-197 (2004).
17. D. A. Haugen, T. A. van der Hoeven, and M. J. Coon. Purified liver microsomal cytochrome P-450. Separation and characterization of multiple forms. J. Biol. Chem. 250:3567-3570 (1975).
18. A. Hildebrandt, H. Remmer, and R. W. Estabrook. Cytochrome P-450 of liver microsomes-one pigment or many Biochem. Biophys. Res. Commun. 30:607-612 (1968).
19. D. W. Nebert. Multiple forms of inducible drug-metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity Mol. Cell. Biochem. 27:27-46 (1979).
20. N. E. Sladek and G. J. Mannering. Induction of drug metabolism. II. Qualitative differences in the microsomal N-demethylating systems stimulated by polycyclic hydrocarbons and by phenobarbital Mol. Pharmacol. 5:186-199 (1969).
21. P. B. Danielson. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans Curr. Drug Metab. 3:561-597 (2002).
22. S. D. Aust, D. L. Roerig, and T. C. Pederson. Evidence for superoxide generation by NADPH-cytochrome c reductase of rat liver microsomes Biochem. Biophys. Res. Commun. 47:1133-1137 (1972).
23. J. T. Groves and G. A. McClusky. Aliphatic hydroxylation by highly purified liver microsomal cytochrome P-450. Evidence for a carbon radical intermediate Biochem. Biophys. Res. Commun. 81:154-160 (1978).
24. F. P. Guengerich. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity Chem. Res. Toxicol. 14:611-650 (2001).
25. P. R. Ortiz de Montellano. Oxygen Activation and Reactivity, Cytochrome P450: Structure, Mechanisms, and Biochemistry. Plenum, New York, 1995, pp. 243-303.
26. P. R. Ortiz de Montellano and J. J. De Voss. Substrate oxidation by cytochrome P450 enzymes. In P. R. O. d. Montellano (ed.), Cytochrome P450: Structure, Mechanisms, and Biochemistry, Plenum, New York, 2004, pp. 183-230.
27. R. A. Sheldon and J. K. Kochi. Activation of Molecular Oxygen by Metal Complexes. Metal-catalyzed Oxidations of Organic Compounds. Academic, New York, 1981, pp. 108-112.
28. H. W. Strobel and M. J. Coon. Effect of superoxide generation and dismutation on hydroxylation reactions catalyzed by liver microsomal cytochrome P-450 J. Biol. Chem. 246:7826-7829 (1971).
29. S. Chen, J. E. Shively, S. Nakajin, M. Shinoda, and P. F. Hall. Amino terminal sequence analysis of human placenta aromatase Biochem. Biophys. Res. Commun. 135:713-719 (1986).
30. A. Mahgoub, J. R. Idle, L. G. Dring, R. Lancaster, and R. L. Smith. Polymorphic hydroxylation of Debrisoquine in man Lancet 2:584-586 (1977).
31. W. L. Miller. Congenital adrenal hyperplasia N. Engl. J. Med. 314:1321-1322 (1986).
32. D. W. Nebert and D. W. Russell. Clinical importance of the cytochromes P450 Lancet 360:1155-1162 (2002).
33. E. C. Miller and J. A. Miller. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules Cancer 47:2327-2345 (1981).
34. U. Groth and H. G. Neumann. The relevance of chemicobiological interactions for the toxic and carcinogenic effects of aromatic amines. V. The pharmacokinetics of related aromatic amines in blood Chem. Biol. Interact. 4:409-419 (1972).
35. D. J. Jollow, J. R. Mitchell, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo J. Pharmacol. Exp. Ther. 187:195-202 (1973).
36. W. Z. Potter, D. C. Davis, J. R. Mitchell, D. J. Jollow, J. R. Gillette, and B. B. Brodie. Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro J. Pharmacol. Exp. Ther. 187:203-210 (1973).
37. I. Gardner, M. Popovic, N. Zahid, and J. P. Uetrecht. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo Chem. Res. Toxicol. 18:1384-1394 (2005).
38. A. S. Kalgutkar, I. Gardner, R. S. Obach, C. L. Shaffer, E. Callegari, K. R. Henne, A. E. Mutlib, D. K. Dalvie, J. S. Lee, Y. Nakai, J. P. O'Donnell, J. Boer, and S. P. Harriman. A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6:161-225 (2005).
39. N. R. Pumford and N. C. Halmes. Protein targets of xenobiotic reactive intermediates Annu. Rev. Pharmacol. Toxicol. 37:91-117 (1997).
40. J. Uetrecht. Prediction of a new drug's potential to cause idiosyncratic reactions Curr. Opin. Drug. Discov. Dev. 4:55-59 (2001).
41. S. Zhou, E. Chan, W. Duan, M. Huang, and Y. Z. Chen. Drug bioactivation, covalent binding to target proteins and toxicity relevance Drug Metab. Rev. 37:41-213 (2005).
42. E. Fontana, P. M. Dansette, and S. M. Poli. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity Curr. Drug Metab. 6:413-454 (2005).
43. S. Zhou, E. Chan, L. Y. Lim, U. A. Boelsterli, S. C. Li, J. Wang, Q. Zhang, M. Huang, and A. Xu. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4 Curr. Drug Metab. 5:415-442 (2004).
44. S. Zhou, S. Yung Chan, B. Cher Goh, E. Chan, W. Duan, M. Huang, and H. L. McLeod. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clin. Pharmacokinet. 44:279-304 (2005).
45. M. Eichelbaum, M. Ingelman-Sundberg, and W. E. Evans. Pharmacogenomics and individualized drug therapy Annu. Rev. Med. 57:119-137 (2006).
46. G. S. Ginsburg, R. P. Konstance, J. S. Allsbrook, and K. A. Schulman. Implications of pharmacogenomics for drug development and clinical practice Arch. Intern. Med. 165:2331-2336 (2005).
47. D. B. Goldstein, S. K. Tate, and S. M. Sisodiya. Pharmacogenetics goes genomic Nat. Rev., Genet. 4:937-947 (2003).
48. D. W. Nebert. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Genet. 56:247-258 (1999).
49. A. Hedgecoe and P. Martin. The drugs don't work: expectations and the shaping of pharmacogenetics Soc. Stud. Sci. 33:327-364 (2003).
50. C. R. Wolf, G. Smith, and R. L. Smith. Science, medicine, and the future: Pharmacogenetics BMJ 320:987-990 (2000).
51. K. A. Frazer, L. Elnitski, D. M. Church, I. Dubchak, and R. C. Hardison. Cross-species sequence comparisons: a review of methods and available resources. Genome Res. 13:1-12 (2003).
52. K. A. Frazer, J. B. Sheehan, R. P. Stokowski, X. Chen, R. Hosseini, J. F. Cheng, S. P. Fodor, D. R. Cox, and N. Patil. Evolutionarily conserved sequences on human chromosome 21 Genome Res. 11:1651-1659 (2001).
53. M. A. Higgins, B. R. Berridge, B. J. Mills, A. E. Schultze, H. Gao, G. H. Searfoss, T. K. Baker, and T. P. Ryan. Gene expression analysis of the acute phase response using a canine microarray Toxicol. Sci. 74:470-484 (2003).
54. N. Kato, M. Shibutani, H. Takagi, C. Uneyama, K. Y. Lee, S. Takigami, K. Mashima, and M. Hirose. Gene expression profile in the livers of rats orally administered ethinylestradiol for 28 days using a microarray technique Toxicology 200:179-192 (2004).
55. G. H. Searfoss, W. H. Jordan, D. O. Calligaro, E. J. Galbreath, L. M. Schirtzinger, B. R. Berridge, H. Gao, M. A. Higgins, P. C. May, and T. P. Ryan. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor J. Biol. Chem. 278:46107-46116 (2003).
56. B. Alexanderson, D. A. Evans, and F. Sjoqvist. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy Br. Med. J. 4:764-768 (1969).
57. W. Hammer and F. Sjoqvist. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds Life Sci. 6:1895-1903 (1967).
58. M. Eichelbaum. Polymorphic oxidation of debrisoquine and sparteine Prog. Clin. Biol. Res. 214:157-167 (1986).
59. R. L. Smith. The Paton Prize Award. The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences Toxicology 168:11-19 (2001).
60. L. Bertilsson. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 Clin. Pharmacokinet. 29:192-209 (1995).
61. C. Bruhn, J. Brockmoller, I. Cascorbi, I. Roots, and H. H. Borchert. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1) Biochem. Pharmacol. 58:1759-1764 (1999).
62. T. K. Chang, L. Yu, J. A. Goldstein, and D. J. Waxman. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation Pharmacogenetics 7:211-221 (1997).
63. A. K. Daly, S. Cholerton, W. Gregory, and J. R. Idle. Metabolic polymorphisms Pharmacol. Ther. 57:129-160 (1993).
64. S. Garte, L. Gaspari, A. K. Alexandrie, C. Ambrosone, H. Autrup, J. L. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, C. Bouchardy, K. Breskvar, J. Brockmoller, I. Cascorbi, M. L. Clapper, C. Coutelle, A. Daly, M. Dell'Omo, V. Dolzan, C. M. Dresler, A. Fryer, A. Haugen, D. W. Hein, A. Hildesheim, A. Hirvonen, L. L. Hsieh, M. Ingelman-Sundberg, I. Kalina, D. Kang, M. Kihara, C. Kiyohara, P. Kremers, P. Lazarus, L. Le Marchand, M. C. Lechner, E. M. van Lieshout, S. London, J. J. Manni, C. M. Maugard, S. Morita, V. Nazar-Stewart, K. Noda, Y. Oda, F. F. Parl, R. Pastorelli, I. Persson, W. H. Peters, A. Rannug, T. Rebbeck, A. Risch, L. Roelandt, M. Romkes, D. Ryberg, J. Salagovic, B. Schoket, J. Seidegard, P. G. Shields, E. Sim, D. Sinnet, R. C. Strange, I. Stucker, H. Sugimura, J. To-Figueras, P. Vineis, M. C. Yu, and E. Taioli. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomark. Prev. 10:1239-1248 (2001).
65. J. A. Goldsteinand and S. M. Moraisde. Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 4:285-299 (1994).
66. S. Hoffmeyer, O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478 (2000).
67. M. Iwasaki, Y. Yoshimura, S. Asahi, K. Saito, S. Sakai, S. Morita, O. Takenaka, T. Inoda, E. Kashiyama, A. Aoyama, T. Nakabayashi, S. Omori, T. Kuwabara, T. Izumi, K. Nakamura, K. Takanaka, Y. Nakayama, M. Takeuchi, H. Nakamura, S. Kametani, Y. Terauchi, T. Hashizume, S. Nagayama, T. Kume, M. Achira, H. Kawai, T. Kawashiro, A. Nakamura, Y. Nakai, A. Kagayama, T. Shiraga, T. Niwa, T. Yoshimura, J. Morita, F. Ohsawa, M. Tani, N. Osawa, K. Ida, and K. Noguchi. Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population Drug Metab. Pharmacokinet. 19:444-452 (2004).
68. I. Johansson, Q. Y. Yue, M. L. Dahl, M. Heim, J. Sawe, L. Bertilsson, U. A. Meyer, F. Sjoqvist, and M. Ingelman-Sundberg. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine Eur. J. Clin. Pharmacol. 40:553-556 (1991).
69. U. A. Meyer and U. M. Zanger. Molecular mechanisms of genetic polymorphisms of drug metabolism Annu. Rev. Pharmacol. Toxicol. 37:269-296 (1997).
70. S. Ohgiya, M. Komori, H. Ohi, K. Shiramatsu, N. Shinriki, and T. Kamataki. Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity Biochem. Int. 27:1073-1081 (1992).
71. K. C. Ferdinand. Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety Expert Rev. Cardiovasc. Ther. 3:993-1001 (2005).
72. S. B. Hagaand and G. S. Ginsburg. Prescribing BiDil: is it black and white? J. Am. Coll. Cardiol. 48:12-14 (2006).
73. D. M. Maraganore, M. Andradede, T. G. Lesnick, K. J. Strain, M. J. Farrer, W. A. Rocca, P. V. Pant, K. A. Frazer, D. R. Cox, and D. G. Ballinger. High-resolution whole-genome association study of Parkinson disease Am. J. Hum. Genet. 77:685-693 (2005).
74. B. Brodie, J. Axelrod, J. R. Cooper, L. Gaudette, B. N. DuLa, C. Mitoma, and S. Udenfriend. Detoxication of drugs and other foreign compounds by liver microsomes Science 121:603-604 (1955).
75. D. Garfinkel. Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions Arch. Biochem. Biophys. 77:493-509 (1958).
76. M. Klingenberg. Pigments of rat liver microsomes Arch. Biochem. Biophys. 75:376-386 (1958).
77. A. Y. Lu, K. W. Junk, and M. J. Coon. Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components J. Biol. Chem. 244:3714-3721 (1969).
78. D. W. Nebert and L. L. Bausserman. Genetic differences in the extent of aryl hydrocarbon hydroxylase induction in mouse fetal cell cultures J. Biol. Chem. 245:6373-6382 (1970).
79. A. B. Okey, G. P. Bondy, M. E. Mason, D. W. Nebert, C. J. Forster-Gibson, J. Muncan, and M. J. Dufresne. Temperature-dependent cytosol-to-nucleus translocation of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in continuous cell culture lines J. Biol. Chem. 255:11415-11422 (1980).
80. J. E. Gielen and D. W. Nebert. Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. I. Stimulation of enzyme activity in nonhepatic cells and in hepatic cells by phenobarbital, polycyclic hydrocarbons, and 2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane J. Biol. Chem. 246:5189-5198 (1971).
81. J. Gorski and F. Gannon. Current models of steroid hormone action: a critique Annu. Rev. Physiol. 38:425-450 (1976).
82. T. M. Guenthner and D. W. Nebert. Cytosolic receptor for aryl hydrocarbon hydroxylase induction by polycyclic aromatic compounds. Evidence for structural and regulatory variants among established cell cultured lines J. Biol. Chem. 252:8981-8989 (1977).
83. A. Poland, E. Glover, and A. S. Kende. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase J. Biol. Chem. 251:4936-4946 (1976).
84. G. Bertilsson, J. Heidrich, K. Svensson, M. Asman, L. Jendeberg, M. Sydow-Backman, R. Ohlsson, H. Postlind, P. Blomquist, and A. Berkenstam. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction Proc. Natl. Acad. Sci. USA 95:12208-12213 (1998).
85. B. Blumberg, W. Sabbagh, Jr., H. Juguilon, J. Bolado, Jr., C. M. van Meter, E. S. Ong, and R. M. Evans. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:3195-3205 (1998).
86. S. A. Kliewer, J. T. Moore, L. Wade, J. L. Staudinger, M. A. Watson, S. A. Jones, D. D. McKee, B. B. Oliver, T. M. Willson, R. H. Zetterstrom, T. Perlmann, and J. M. Lehmann. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway Cell 92:73-82 (1998).
87. S. A. Kliewer, J. M. Lehmann, and T. M. Willson. Orphan nuclear receptors: shifting endocrinology into reverse Science 284:757-760 (1999).
88. J. J. Repa and D. J. Mangelsdorf. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis Annu. Rev. Cell Dev. Biol. 16:459-481 (2000).
89. T. H. Rushmore and A. N. Kong. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes Curr. Drug Metab. 3:481-490 (2002).
90. J. H. Lin. Tissue distribution and pharmacodynamics: a complicated relationship Curr. Drug Metab. 7:39-65 (2006).
91. J. Brockmoller, J. Kirchheiner, C. Meisel, and I. Roots. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment Pharmacogenomics 1:125-151 (2000).
92. M. Eichelbaum. Pharmacokinetic drug interactions J. Clin. Pharmacol. 26:469-473 (1986).
93. M. T. Zuhlsdorf. Relevance of pheno- and genotyping in clinical drug development Int. J. Clin. Pharmacol. Ther. 36:607-612 (1998).
94. R. Weinshilboum. Inheritance and drug response N. Engl. J. Med. 348:529-537 (2003).
95. M. Ingelman-Sundberg. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms Naunyn-Schmiedebergs Arch. Pharmacol 369:89-104 (2004).
96. W. E. Evans and M. V. Relling. Pharmacogenomics: translating functional genomics into rational therapeutics Science 286:487-491 (1999).
97. M. M. Shi, M. R. Bleavins, and F. A. Iglesiade la. Pharmacogenetic application in drug development and clinical trials Drug Metab. Dispos. 29:591-595 (2001).
98. M. W. Linder, R. A. Prough, and R. Valdes, Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem.43:254-266 (1997).
99. T. Friedberg, M. P. Pritchard, M. Bandera, S. P. Hanlon, D. Yao, L. A. McLaughlin, S. Ding, B. Burchell, and C. R. Wolf. Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison Drug Metab. Rev. 31:523-544 (1999).
100. C. J. Henderson and C. R. Wolf. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology Mol. Interv. 3:331-343 (2003).
101. I. S. Vizirianakis. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice Curr. Drug Deliv. 1:73-80 (2004).
102. C. R. Wolf. The Gerhard Zbinden memorial lecture: application of biochemical and genetic approaches to understanding pathways of chemical toxicity Toxicol. Lett. 127:3-17 (2002).
103. P. M. Holland, R. D. Abramson, R. Watson, and D. H. Gelfand. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase Proc. Natl. Acad. Sci. USA 88:7276-7280 (1991).
104. P. W. Kleyn and E. S. Vesell. Genetic variation as a guide to drug development Science 281:1820-1821 (1998).
105. G. Luo, M. Cunningham, S. Kim, T. Burn, J. Lin, M. Sinz, G. Hamilton, C. Rizzo, S. Jolley, D. Gilbert, A. Downey, D. Mudra, R. Graham, K. Carroll, J. Xie, A. Madan, A. Parkinson, D. Christ, B. Selling, E. LeCluyse, and L. S. Gan. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes Drug Metab. Dispos. 30:795-804 (2002).
106. L. G. Yengi, Q. Xiang, J. Pan, J. Scatina, J. Kao, S. E. Ball, R. Fruncillo, G. Ferron, and C. Roland Wolf. Quantitation of cytochrome P450 mRNA levels in human skin Anal. Biochem. 316:103-110 (2003).
107. FDA. Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, 2006.
108. L. G. Yengi. Systems biology in drug safety and metabolism: integration of microarray, real-time PCR and enzyme approaches Pharmacogenomics 6:185-192 (2005).
109. C. Debouck and P. N. Goodfellow. DNA microarrays in drug discovery and development Nat. Genet. 21:48-50 (1999).
110. C. A. Harrington, C. Rosenow, and J. Retief. Monitoring gene expression using DNA microarrays Curr. Opin. Microbiol. 3:285-291 (2000).
111. R. J. Lipshutz, S. P. Fodor, T. R. Gingeras, and D. J. Lockhart. High density synthetic oligonucleotide arrays Nat. Genet. 21:20-24 (1999).
112. C. J. Henderson, D. M. Otto, D. Carrie, M. A. Magnuson, A. W. McLaren, I. Rosewell, and C. R. Wolf. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278:13480-13486 (2003).
113. E. LeCluyse, A. Madan, G. Hamilton, K. Carroll, R. DeHaan, and A. Parkinson. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes J. Biochem. Mol. Toxicol. 14:177-188 (2000).
114. A. P. Li, S. M. Colburn, and D. J. Beck. A simplified method for the culturing of primary adult rat and human hepatocytes as multicellular spheroids In Vitro Cell Dev. Biol. 28A:673-677 (1992).
115. R. E. Pearce, C. J. McIntyre, A. Madan, U. Sanzgiri, A. J. Draper, P. L. Bullock, D. C. Cook, L. A. Burton, J. Latham, C. Nevins, and A. Parkinson. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity Arch. Biochem. Biophys. 331:145-169 (1996).
116. A. P. Li, D. L. Kaminski, and A. Rasmussen. Substrates of human hepatic cytochrome P450 3A4 Toxicology 104:1-8 (1995).
117. J. D. Cleary, L. A. Walker, and R. L. Hawke. Antimycotic drug discovery in the age of genomics Am. J. Pharmacogenomics 5:365-386 (2005).
118. D. Gerhold, M. Lu, J. Xu, C. Austin, C. T. Caskey, and T. Rushmore. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays Physiol. Genomics. 5:161-170 (2001).
119. D. J. McConn and Z. Zhao. Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: in vitro study design Curr. Drug Metab. 5:141-146 (2004).
120. G. Luo, J. Lin, W. D. Fiske, R. Dai, T. J. Yang, S. Kim, M. Sinz, E. LeCluyse, E. Solon, J. M. Brennan, I. H. Benedek, S. Jolley, D. Gilbert, L. Wang, F. W. Lee, and L. S. Gan. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative Drug Metab. Dispos. 31:1170-1175 (2003).
121. Y. Konno, M. Sekimoto, K. Nemoto, and M. Degawa. Sex difference in induction of hepatic CYP2B and CYP3A subfamily enzymes by nicardipine and nifedipine in rats Toxicol. Appl. Pharmacol. 196:20-28 (2004).
122. D. Projean, S. Dautrey, H. K. Vu, T. Groblewski, J. L. Brazier, and J. Ducharme. Selective downregulation of hepatic cytochrome P450 expression and activity in a rat model of inflammatory pain Pharm. Res. 22:62-70 (2005).
123. M. P. Murphy. Current pharmacogenomic approaches to clinical drug development Pharmacogenomics 1:115-123 (2000).
124. B. Goodwin, E. Hodgson, and C. Liddle. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module Mol. Pharmacol. 56:1329-1339 (1999).
125. N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama. Impact of drug transporter studies on drug discovery and development Pharmacol. Rev. 55:425-461 (2003).
126. P. M. Beringer and R. L. Slaughter. Transporters and their impact on drug disposition Ann. Pharmacother. 39:1097-1108 (2005).
127. K. Ito, H. Suzuki, T. Horie, and Y. Sugiyama. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport Pharm. Res. 22:1559-1577 (2005).
128. J. H. Lin. Species similarities and differences in pharmacokinetics Drug Metab. Dispos. 23:1008-1021 (1995).
129. Y. Sai. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition Drug Metab. Pharmacokinet. 20:91-99 (2005).
130. J. E. van Montfoort, B. Hagenbuch, G. M. Groothuis, H. Koepsell, P. J. Meier, and D. K. Meijer. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4:185-211 (2003).
131. A. Bodo, E. Bakos, F. Szeri, A. Varadi, and B. Sarkadi. The role of multidrug transporters in drug availability, metabolism and toxicity Toxicol. Lett. 140-141:133-143 (2003).
132. K. M. Mahar Doan, J. E. Humphreys, L. O. Webster, S. A. Wring, L. J. Shampine, C. J. Serabjit-Singh, K. K. Adkison, and J. W. Polli. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 303:1029-1037 (2002).
133. G. K. Dresser, D. G. Bailey, B. F. Leake, U. I. Schwarz, P. A. Dawson, D. J. Freeman, and R. B. Kim. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin. Pharmacol. Ther. 71:11-20 (2002).
134. M. Cvetkovic, B. Leake, M. F. Fromm, G. R. Wilkinson, and R. B. Kim. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab. Dispos. 27:866-871 (1999).
135. M. Masuda, Y. I'Izuka, M. Yamazaki, R. Nishigaki, Y. Kato, K. Ni'inuma, H. Suzuki, and Y. Sugiyama. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats Cancer Res. 57:3506-3510 (1997).
136. S. Seitz and U. A. Boelsterli. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats Gastroenterology 115:1476-1482 (1998).
137. B. Stieger, K. Fattinger, J. Madon, G. A. Kullak-Ublick, and P. J. Meier. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver Gastroenterology 118:422-430 (2000).
138. C. Funk, M. Pantze, L. Jehle, C. Ponelle, G. Scheuermann, M. Lazendic, and R. Gasser. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate Toxicology 167:83-98 (2001).
139. T. Korjamo, P. Honkakoski, M. R. Toppinen, S. Niva, M. Reinisalo, J. J. Palmgren, and J. Monkkonen. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines Eur. J. Pharm. Sci. 26:266-279 (2005).
140. J. W. Polli, S. A. Wring, J. E. Humphreys, L. Huang, J. B. Morgan, L. O. Webster, and C. S. Serabjit-Singh. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 299:620-628 (2001).
141. P. P. Annaert and K. L. Brouwer. Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes Drug Metab. Dispos. 33:388-394 (2005).
142. P. P. Annaert, R. Z. Turncliff, C. L. Booth, D. R. Thakker, and K. L. Brouwer. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes Drug Metab. Dispos. 29:1277-1283 (2001).
143. W. Lee, H. Glaeser, L. H. Smith, R. L. Roberts, G. W. Moeckel, G. Gervasini, B. F. Leake, and R. B. Kim. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280:9610-9617 (2005).
144. M. Sasaki, H. Suzuki, J. Aoki, K. Ito, P. J. Meier, and Y. Sugiyama. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2 Mol. Pharmacol. 66:450-459 (2004).
145. H. Ishizuka, K. Konno, T. Shiina, H. Naganuma, K. Nishimura, K. Ito, H. Suzuki, and Y. Sugiyama. Species differences in the transport activity for organic anions across the bile canalicular membrane J. Pharmacol. Exp. Ther. 290:1324-1330 (1999).
146. A. D. Shilling, F. Azam, J. Kao, and L. Leung. Use of canalicular membrane vesicles (CMVs) from rats, dogs, monkeys and humans to assess drug transport across the canalicular membrane J. Pharmacol. Toxicol. Methods 53:186-197 (2006).
147. J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios Drug Metab. Dispos. 32:1201-1208 (2004).
148. J. B. Houston and D. J. Carlile. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices Drug Metab. Rev. 29:891-922 (1997).
149. H. M. Jones and J. B. Houston. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations Drug Metab. Dispos. 32:973-982 (2004).
150. R. S. Obach. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 27:1350-1359 (1999).
151. S. X. Zhao, D. Forman, N. Wallace, B. J. Smith, D. Meyer, D. Kazolias, F. Gao, J. Soglia, M. Cole, and D. Nettleton. Simple strategies for reducing sample loads in in in vitro metabolic stability high-throughput screening experiments: a comparison between traditional, two-time-point and pooled sample analyses J. Pharm. Sci. 94:38-45 (2005).
152. Y. Naritomi, S. Terashita, A. Kagayama, and Y. Sugiyama. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro Drug Metab. Dispos. 31:580-588 (2003).
153. R. J. Riley, D. F. McGinnity, and R. P. Austin. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes Drug Metab. Dispos. 33:1304-1311 (2005).
154. Y. Shibata, H. Takahashi, M. Chiba, and Y. Ishii. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method Drug Metab. Dispos. 30:892-896 (2002).
155. L. P. Delbressine, C. W. Funke, M. Tilborgvan, and F. M. Kaspersen. On the formation of carbamate glucuronides Xenobiotica 20:133-134 (1990).
156. S. D. Hall, K. E. Thummel, P. B. Watkins, K. S. Lown, L. Z. Benet, M. F. Paine, R. R. Mayo, D. K. Turgeon, D. G. Bailey, R. J. Fontana, and S. A. Wrighton. Molecular and physical mechanisms of first-pass extraction Drug Metab. Dispos. 27:161-166 (1999).
157. M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, and D. C. Zeldin. The human intestinal cytochrome P450 "pie" Drug Metab. Dispos. 34:880-886 (2006).
158. C. Y. Wu and L. Z. Benet. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22:11-23 (2005).
159. C. L. Cummins, W. Jacobsen, U. Christians, and L. Z. Benet. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam J. Pharmacol. Exp. Ther. 308:143-155 (2004).
160. M. F. Paine, L. Y. Leung, H. K. Lim, K. Liao, A. Oganesian, M. Y. Zhang, K. E. Thummel, and P. B. Watkins. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion J. Pharmacol. Exp. Ther. 301:174-186 (2002).
161. L. Y. Leung, H. K. Lim, M. W. Abell, and J. J. Zimmerman. Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose Ther. Drug Monit. 28:51-61 (2006).
162. R. L. Woosley, Y. Chen, J. P. Freiman, and R. A. Gillis. Mechanism of the cardiotoxic actions of terfenadine JAMA 269:1532-1536 (1993).
163. A. Markham and A. J. Wagstaff. Fexofenadine Drugs 55:269-274 (1998).
164. P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor Drug Metab. Dispos. 31:1352-1360 (2003).
165. T. M. Polasek, D. J. Elliot, B. C. Lewis, and J. O. Miners. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J. Pharmacol. Exp. Ther.311:996-1007 (2004).
166. Z. Y. Zhang and Y. N. Wong. Enzyme kinetics for clinically relevant CYP inhibition Curr. Drug Metab. 6:241-257 (2005).
167. T. D. Bjornsson, J. T. Callaghan, H. J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni, G. Kumar, J. McLeod, R. S. Obach, S. Roberts, A. Roe, A. Shah, F. Snikeris, J. T. Sullivan, D. Tweedie, J. M. Vega, J. Walsh, and S. A. Wrighton. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab. Dispos. 31:815-832 (2003).
168. W. Tang, R. W. Wang, and A. Y. Lu. Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective Curr. Drug Metab. 6:503-517 (2005).
169. A. L. Blobaum. Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes? Drug Metab. Dispos. 34:1-7 (2006).
170. E. A. Dierks, K. R. Stams, H. K. Lim, G. Cornelius, H. Zhang, and S. E. Ball. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry Drug Metab. Dispos. 29:23-29 (2001).
171. K. Ito, D. Hallifax, R. S. Obach, and J. B. Houston. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm Drug Metab. Dispos. 33:837-844 (2005).
172. B. S. Mayhew, D. R. Jones, and S. D. Hall. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation Drug Metab. Dispos. 28:1031-1037 (2000).
173. J. P. O'Donnell, D. K. Dalvie, A. S. Kalgutkar, and R. S. Obach. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen Drug Metab. Dispos. 31:1369-1377 (2003).
174. Y. H. Wang, D. R. Jones, and S. D. Hall. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites Drug Metab. Dispos. 32:259-266 (2004).
175. J. Yang, M. Jamei, K. R. Yeo, G. T. Tucker, and A. Rostami-Hodjegan. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol Eur. J. Pharm. Sci. 26:334-340 (2005).
176. N. Greene, P. N. Judson, J. J. Langowski, and C. A. Marchant. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR SAR QSAR Environ. Res. 10:299-314 (1999).
177. H. K. Lim, N. Duczak Jr., L. Brougham, M. Elliot, K. Patel, and K. Chan. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes Drug Metab. Dispos. 33:1211-1219 (2005).
178. K. M. Bertelsen, K. Venkatakrishnan, L. L. Von Moltke, R. S. Obach, and D. J. Greenblatt. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31:289-293 (2003).
179. A. Hemeryck and F. M. Belpaire. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update Curr. Drug Metab. 3:13-37 (2002).
180. K. Venkatakrishnan and R. S. Obach. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude Drug Metab. Dispos. 33:845-852 (2005).
181. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider, J. H. Lin, and T. A. Baillie. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations Br. J. Clin. Pharmacol. 47:291-298 (1999).
182. C. Wandel, R. B. Kim, F. P. Guengerich, and A. J. Wood. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro Drug Metab. Dispos. 28:895-898 (2000).
183. F. Longuevillede, F. A. Atienzar, L. Marcq, S. Dufrane, S. Evrard, L. Wouters, F. Leroux, V. Bertholet, B. Gerin, R. Whomsley, T. Arnould, J. Remacle, and M. Canning. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes Toxicol. Sci. 75:378-392 (2003).
184. M. R. Fielden and T. R. Zacharewski. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology Toxicol. Sci. 60:6-10 (2001).
185. T. Storck, M. C. von Brevern, C. K. Behrens, J. Scheel, and A. Bach. Transcriptomics in predictive toxicology. Curr. Opin. Drug Discov. Dev. 5:90-97 (2002).
186. F. Boess, M. Kamber, S. Romer, R. Gasser, D. Muller, S. Albertini, and L. Suter. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci.73:386-402 (2003).
187. J. F. Waring, G. Cavet, R. A. Jolly, J. McDowell, H. Dai, R. Ciurlionis, C. Zhang, R. Stoughton, P. Lum, A. Ferguson, C. J. Roberts, and R. G. Ulrich. Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences EHP Toxicogenomics 111:53-60 (2003).
188. R. A. Roth, J. P. Luyendyk, J. F. Maddox, and P. E. Ganey. Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther.307:1-8 (2003).
189. D. P. Williams, N. R. Kitteringham, D. J. Naisbitt, M. Pirmohamed, D. A. Smith, and B. K. Park. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. Drug Metab. 3:351-366 (2002).
190. D. C. Liebler and F. P. Guengerich. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov. 4:410-420 (2005).
191. J. Uetrecht. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions Drug Discov. Today 8:832-837 (2003).
192. C. Chen, J. L. Staudinger, and C. D. Klaassen. Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile Drug Metab. Dispos. 31:908-915 (2003).
193. J. P. Nagpal, K. L. Khanduja, R. R. Sharma, S. Majumdar, R. Singh, M. P. Gupta, and S. C. Dogra. The effect of medroxyprogesterone acetate on the hepatic drug-metabolizing enzymes in normal and protein-deficient female rats Biochem. Med. 34:11-16 (1985).
194. H. U. Saarni. Time course of hepatic changes produced by medroxyprogesterone acetate in the rat Gen. Pharmacol. 17:25-29 (1986).
195. L. G. Yengi, Q. Xiang, L. Shen, C. Appavu, J. Kao, and J. Scatina. Application of pharmacogenomics in drug discovery and development: correlations between transcriptional modulation and preclinical safety observation. Drug metab. Lett 1:(2007).
196. I. Kola and J. Landis. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711-715 (2004).
197. M. P. Murphy, M. Bickel, D. Birkett, B. Clement, R. W. Estabrook, J. Gorrod, J. Hinson, P. Kissinger, T. Kunze, P. Maurel, P. Van Bladeren, and C. R. Wolf. History of Xenobiotic Metabolism. http://www.issx.org.